185 related articles for article (PubMed ID: 38118373)
1. Pharmacotherapy for leptomeningeal disease in breast cancer.
Bartsch R; Jerzak KJ; Larrouquere L; Müller V; Le Rhun E
Cancer Treat Rev; 2024 Jan; 122():102653. PubMed ID: 38118373
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
3. Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
Kingston B; Kayhanian H; Brooks C; Cox N; Chaabouni N; Redana S; Kalaitzaki E; Smith I; O'Brien M; Johnston S; Parton M; Noble J; Stanway S; Ring A; Turner N; Okines A
Breast; 2017 Dec; 36():54-59. PubMed ID: 28968585
[TBL] [Abstract][Full Text] [Related]
4. A Review on the Efficacy and Safety of Intrathecal Administration of Novel Medications for Leptomeningeal Metastases in Solid Cancers.
Jafari F; Nodeh MM; Hosseinjani H; Baharara H; Azad S; Arasteh O; Johnston TP; Sahebkar A
Curr Med Chem; 2024; 31(19):2732-2750. PubMed ID: 37157199
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.
Kumthekar PU; Avram MJ; Lassman AB; Lin NU; Lee E; Grimm SA; Schwartz M; Bell Burdett KL; Lukas RV; Dixit K; Perron I; Zhang H; Gradishar WJ; Pentsova EI; Jeyapalan S; Groves MD; Melisko M; Raizer JJ
Neuro Oncol; 2023 Mar; 25(3):557-565. PubMed ID: 35948282
[TBL] [Abstract][Full Text] [Related]
6. [Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
Gutierrez M; Lyazidi S; Brasseur L; Cvitkovic F; Le Scodan R
Bull Cancer; 2011 Apr; 98(4):417-24. PubMed ID: 21540147
[TBL] [Abstract][Full Text] [Related]
7. Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape.
Nguyen A; Nguyen A; Dada OT; Desai PD; Ricci JC; Godbole NB; Pierre K; Lucke-Wold B
Curr Oncol; 2023 Jun; 30(6):5906-5931. PubMed ID: 37366925
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
[TBL] [Abstract][Full Text] [Related]
9. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E; Kebir S; Ahmed MS; Keyvani K; Umutlu L; Kanaki T; Zaremba A; Reinboldt-Jockenhoefer F; Knispel S; Gratsias E; Roesch A; Ugurel S; Scheffler B; Schadendorf D; Livingstone E; Meier F; Glas M; Zimmer L
Eur J Cancer; 2021 May; 148():395-404. PubMed ID: 33789203
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis.
Yust-Katz S; Garciarena P; Liu D; Yuan Y; Ibrahim N; Yerushalmi R; Penas-Prado M; Groves MD
J Neurooncol; 2013 Sep; 114(2):229-35. PubMed ID: 23756727
[TBL] [Abstract][Full Text] [Related]
11. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
Lazaratos AM; Maritan SM; Quaiattini A; Darlix A; Ratosa I; Ferraro E; Griguolo G; Guarneri V; Pellerino A; Hofer S; Jacot W; Stemmler HJ; van den Broek MPH; Dobnikar N; Panet F; Lahijanian Z; Morikawa A; Seidman AD; Soffietti R; Panasci L; Petrecca K; Rose AAN; Bouganim N; Dankner M
Breast; 2023 Jun; 69():451-468. PubMed ID: 37156650
[TBL] [Abstract][Full Text] [Related]
12. Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease.
Mills MN; King W; Soyano A; Pina Y; Czerniecki BJ; Forsyth PA; Soliman H; Han HS; Ahmed KA
J Neurooncol; 2022 Apr; 157(2):249-269. PubMed ID: 35244835
[TBL] [Abstract][Full Text] [Related]
13. Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review.
Fernandes L; de Matos LV; Cardoso D; Saraiva M; Medeiros-Mirra R; Coelho A; Miranda H; Martins A
CNS Oncol; 2020 Dec; 9(4):CNS65. PubMed ID: 33078616
[TBL] [Abstract][Full Text] [Related]
14. Leptomeningeal disease and breast cancer: the importance of tumor subtype.
Abouharb S; Ensor J; Loghin ME; Katz R; Moulder SL; Esteva FJ; Smith B; Valero V; Hortobagyi GN; Melhem-Bertrandt A
Breast Cancer Res Treat; 2014 Aug; 146(3):477-86. PubMed ID: 25038877
[TBL] [Abstract][Full Text] [Related]
15. Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment.
Steininger J; Gellrich FF; Engellandt K; Meinhardt M; Westphal D; Beissert S; Meier F; Glitza Oliva IC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511202
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy in Leptomeningeal Disease: A Systematic Review of Randomized and Non-randomized Trials.
Buszek SM; Chung C
Front Oncol; 2019; 9():1224. PubMed ID: 31803614
[No Abstract] [Full Text] [Related]
17. Breast leptomeningeal disease: a review of current practices and updates on management.
Figura NB; Rizk VT; Armaghani AJ; Arrington JA; Etame AB; Han HS; Czerniecki BJ; Forsyth PA; Ahmed KA
Breast Cancer Res Treat; 2019 Sep; 177(2):277-294. PubMed ID: 31209686
[TBL] [Abstract][Full Text] [Related]
18. Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries.
Lamba N; Cagney DN; Catalano PJ; Elhalawani H; Haas-Kogan DA; Wen PY; Wagle N; Lin NU; Aizer AA; Tanguturi S
Neuro Oncol; 2023 May; 25(5):973-983. PubMed ID: 36367837
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
Wallace G; Kundalia R; Vallebuona E; Cao B; Kim Y; Forsyth P; Soyano A; Smalley I; Pina Y
Breast Cancer Res; 2024 Mar; 26(1):55. PubMed ID: 38553702
[TBL] [Abstract][Full Text] [Related]
20. [Intrathecal methotrexate chemotherapy for leptomeningeal carcinomatosis].
Kullmann T; Gauthier H; le Maignan C; Szabó A; Culine S
Orv Hetil; 2012 Sep; 153(35):1385-8. PubMed ID: 22935431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
